Thomas J. DesRosier
Executive VP, Chief Legal Officer & SecretaryMr. Thomas J. DesRosier, also known as Tom, Esq., J.D., is Chief Legal Officer of Seres Therapeutics, Inc. since May 16, 2016 and was its Co-Chief Executive Officer since July 31, 2025 until March 02, 2026 and served as its Co-President since August 1, 2025 until March 02, 2026 and serves as its Executive Vice President from 2026 and serves as its Secretary. Mr. DesRosier was Executive Vice President and Secretary of Seres Therapeutics, Inc. since May 16, 2016 until July 31, 2025. Mr. DesRosier served as the Chief Legal & Administration Officer, Executive Vice President and Secretary of Ariad Pharmaceuticals Inc. since January 22, 2015 until April 30, 2016. He served as Senior Vice President and General Counsel of North America at Sanofi since 2011 till 2013. He served as an Executive Vice President and served as the Chief Legal and Administrative Officer at Cubist Pharmaceuticals Inc. since February 2014 till 2015. He served as the Chief Legal Officer, Secretary and Senior Vice President of Cubist Pharmaceuticals Inc. since March 2013 till 2014 and Secretary from 2013 to 2015. He served as Senior Vice President and General Counsel of Genzyme Corporation since October 2000. He served as Chief Legal Officer of Genzyme Corporation since May 2008. He served as Chief Legal Officer and Senior Vice President at Sanofi Biosurgery. He served at Genzyme Oncology, Inc., Genzyme Surgical Products and Genzyme Biosurgery Corporation. He was responsible for the management of Genzyme Corporation's legal affairs worldwide, including supervision of more than 50 internal legal professionals. He served as Chief Patent Counsel at Genzyme. Before Genzyme, he was an Assistant General Counsel for patents at American Home Products Corp., where he directed intellectual property efforts for pharmaceutical products. He served as Chief Financial Officer and Executive Vice President at Genzyme Tissue Repair. From 1999 to 2011, Mr. DesRosier held leadership roles of increasing importance within the legal group of Genzyme Corporation. He served as Vice President and Chief Patent Counsel for Genetics Institute Inc. and held several intellectual property positions at EWyeth Pharmaceuticals, Genetics Institute, I. DuPont de Nemours and Company and New England Nuclear Corp. Mr. DesRosier has served as a member of the board of directors of Avanir Pharmaceuticals, a wholly-owned subsidiary of Otsuka Pharmaceutical Company, Ltd. since June 2017. He has years of global biotechnology and pharmaceutical industry experience. Mr. DesRosier earned a JD from Wake Forest University School of Law and a B.A. in Chemistry from the University of Vermont. He had been a Director of Optimer Pharmaceuticals, Inc., since October 24, 2013.
Positions
- Company NameSeres Therapeutics, Inc.Stock CodeMCRBPositionExecutive VP, Chief Legal Officer & SecretaryColleagues
- RNRichard N. KenderInterim CEO & Executive Chair
- MRMatthew R. HennPresident & Chief Scientific Officer
- KBKelly BradyExecutive VP & COO
- CMChris McChalicherExecutive VP & CTO
- KCKurt C. GravesIndependent Director
- WHWillard H. DereIndependent Director
- SAStephen A. BerensonIndependent Director
- EDEric D. ShaffDirector
